Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376400 | 0.85 | RIPK1 (0.37) | RIPK1 | |
| SCHEMBL4373232 | 0.85 | TP53 (0.38) | TP53RIPK1PTGS2SIGMAR1CTSB | |
| SCHEMBL4372778 | 0.85 | RIPK1 (0.41) | TP53RIPK1SIGMAR1 | |
| SCHEMBL4374070 | 0.84 | TP53 (0.37) | TP53RIPK1PTGS2SIGMAR1CTSB | |
| SCHEMBL4374005 | 0.84 | TP53 (0.39) | TP53PTGS2CTSB | |
| SCHEMBL4370615 | 0.82 | TP53 (0.38) | TP53RIPK1SIGMAR1CTSB | |
| SCHEMBL4369990 | 0.82 | TP53 (0.41) | TP53RIPK1PTGS2CTSB | |
| SCHEMBL4376388 | 0.79 | RIPK1 (0.37) | RIPK1 | |
| SCHEMBL4381631 | 0.79 | TP53 (0.35) | TP53 | |
| SCHEMBL15139886 | 0.79 | BRD4 (0.34) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | TP53 2744/4885RIPK1 941/4885PTGS2 3024/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | TP53 4672/4885RIPK1 590/4885PTGS2 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.